New AI software: In spite of the promotion in medicine, detection of tumors continues to be a challenging task with an expansive life-threatening gap between diagnosis and curability.
As science and technology rapidly fade their boundaries, a San Francisco based company called Arterys has acknowledged an FDA clearance to market a first-of-its-kind, AI as-a-service software to help doctors detect, measure, and track tumors and lesions in CT scans of lungs and in MRI and CT scans of the liver, as reported from one of the sources.
The software builds on another AI platform called Cardio AI, which automates the image-analysis functions that the radiologist currently executes manually. By automating, the assessment time is reduced from 30 minutes to just 15 seconds.
For Lungs and Liver, Arterys software is expected to welcome the same efficiency level in examining scans. The company is even looking at including breast scan compatibility to the software.
The approval which was received last month, in February is now allowing software to be used in almost 100 countries. It is right now used in 100 hospitals across the world.
Does this mean no interference of humans when it comes to Diagnosis? CEO Fabien Beckers focusses that the purpose of the software is to provide human radiologists with enhanced information to make a more precise diagnosis in quick time.